Pfizer, Icagen ink deal

Pfizer is investing up to $15 million in Icagen as part of a collaboration and licensing agreement covering potential pain meds. The companies will jointly develop drugs that target three sodium ion channels that mediate the nervous system's pain signals. Pfizer is on the hook for all development costs, but it gets exclusive rights to commercialize any products that arise. The deal sent Icagen shares soaring by more than 69 percent to $3.25, in early trading.

- see the release
- here's the report from the Triangle Business Journal

Related Articles:
Troubled Pfizer blueprints biotech venture effort. Report
What's next for Pfizer? Report
WSJ: Pfizer looks at restructuring R&D, new cuts. Report
Troubled Icagen gains $22M in financing. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.